Results from the phase I clinical trials showed that Tozorakimab significantly reduced serum levels of pro-inflammatory cytokines, particularly IL-5 and IL-13, in patients with chronic obstructive pulmonary disease [52]. Here, IL5 is linked to chronic obstructive pulmonary disease.